Advanced search
Publication Cover
Expert Review of Clinical Pharmacology Volume 9, 2016 - Issue 7
Submit an article Journal homepage
211
Views
7
CrossRef citations to date
0
Altmetric
Review

Pitavastatin and carbohydrate metabolism: what is the evidence?

T. D. FilippatosDepartment of Internal Medicine, School of Medicine, University of Ioannina, Ioannina, Greece
&
M. S. ElisafDepartment of Internal Medicine, School of Medicine, University of Ioannina, Ioannina, GreeceCorrespondence[email protected]
Pages 955-960 | Received 08 Feb 2016, Accepted 10 Mar 2016, Published online: 28 Mar 2016

Citations (7)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

Sebastian Filippas-Ntekouan, Theodosios D. Filippatos & Moses S. Elisaf. (2018) SGLT2 inhibitors: are they safe?. Postgraduate Medicine 130:1, pages 72-82.
Read now
Theodosios Filippatos, Eleftheria Tzavella, Christos Rizos, Moses Elisaf & George Liamis. (2017) Acid-base and electrolyte disorders associated with the use of antidiabetic drugs. Expert Opinion on Drug Safety 16:10, pages 1121-1132.
Read now
T. D. Filippatos, M. Florentin, M. Georgoula & M. S. Elisaf. (2017) Pharmacological management of diabetic dyslipidemia. Expert Review of Clinical Pharmacology 10:2, pages 187-200.
Read now

Articles from other publishers (4)

Ismini Tzanaki, Aris P Agouridis & Michael S Kostapanos. (2022) Is there a role of lipid-lowering therapies in the management of fatty liver disease?. World Journal of Hepatology 14:1, pages 119-139.
Crossref
David S.H. Bell & Edison Goncalves. (2021) Diabetogenic effects of cardioprotective drugs. Diabetes, Obesity and Metabolism 23:4, pages 877-885.
Crossref
Theodosios D. Filippatos, Thalia Panagiotopoulou, Eleftheria Tzavella & Moses S. Elisaf. (2018) Hypolipidemic Drugs and Diabetes Mellitus—Mechanisms and Data From Genetic Trials. Journal of Cardiovascular Pharmacology and Therapeutics 23:3, pages 187-191.
Crossref
Theodosios D. Filippatos, Anastazia Kei & Moses S. Elisaf. (2017) Anacetrapib, a New CETP Inhibitor: The New Tool for the Management of Dyslipidemias?. Diseases 5:4, pages 21.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.